PGNY News and Press, Progyny Inc.

2026-07-10 10:52:36 ET More on Health Care stocks Soft Landing Myth: How This Week's Data Exposed The Hidden Recession Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It IXJ: Healthcare Sector Dashboard For June Biotech rally res...

2026-06-25 13:25:01 ET Mark S. Livingston, Chief Financial Officer of Progyny (NASDAQ:PGNY) , reported the sale of 8,275 shares of common stock in an open-market transaction on May 20, 2026, as disclosed in an SEC Form 4 filing . Transaction value based on SEC Form 4 repor...

2026-06-02 07:38:48 ET More on Health Care stocks AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Notable healthca...

2026-05-31 11:22:49 ET Progyny (NASDAQ:PGNY) delivers fertility benefits to major employers; a key insider recently trimmed their stake, according to SEC filings. Kevin K. Gordon, Director at Progyny, reported the sale of 5,500 shares of common stock for a transaction value of a...

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- A new survey from Progyny (Nasdaq: PGNY), a global leader in women’s health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guida...

2026-05-26 08:24:36 ET More on Progyny Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript Progyny, Inc. 2026 Q1 - Results - Earnings Call Presentation U.S. pro...

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program wi...

2026-05-21 16:40:44 ET Progyny, Inc. (PGNY) Shareholder/Analyst Call May 21, 2026 3:00 PM EDT Company Participants Peter Anevski - CEO & Director Allison Swartz - Executive VP, General Counsel & Secretary James Hart - Vice President of Investor Relations ...

2026-05-15 17:15:02 ET from Barclays issued a price target of $27.00 for PGNY on 2026-05-15 18:56:28. The adjusted price target was set to $27.00. At the time of the announcement, PGNY was trading at $23.25. The overall price target consensus is at $30.80 with high price...

2026-05-15 16:15:02 ET Barclays analyst issues OVERWEIGHT recommendation for PGNY on May 15, 2026 06:56PM ET. The previous analyst recommendation was Overweight. PGNY was trading at $23.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...